Why the Same Drug Does Not Produce One Universal Result

Variability is not a footnote to GLP-1 body-composition evidence; it is the problem that the evidence has to explain. When two reports give different estimates of lean-mass change, the useful response is not to choose the more reassuring or more alarming headline. Ask who was treated, which drug and dose they received, how long they were followed, what happened around the treatment, which method measured the tissue, and whether the result was compared with anything. That sequence turns an apparent contradiction into a set of testable differences.

Time, dose, and regimen are part of the result

A body-composition measurement is a snapshot of a changing treatment. The broader review grouped findings at three, six, and twelve months, but those groups did not follow one uniform population through the same course. At three months, pooled body mass fell by about 9%, fat mass by about 17%, visceral adipose tissue area by about 29.25 square centimeters, and lean body mass by about 2%. At six months, body mass fell by about 5% and fat mass by about 6%; fat-free mass was not significantly changed in the pooled analysis, while the related lean-body-mass estimate fell by about 1% and skeletal muscle mass by about 3%. At twelve months, body mass and fat mass each fell by about 4%, while lean body mass also fell by about 4%, with notable differences between agents.

These figures can look like a biological sequence—large early fat loss, followed by slower change and a larger lean fraction—but the reviews do not establish that exact trajectory for every person. The three-month results came from one set of studies, the six-month results from another, and the twelve-month results from another. Doses, formulations, diabetes status, starting characteristics, lifestyle programs, and measurement methods varied. The authors suggest that adherence, adaptive metabolic responses, and changes in lifestyle recommendations may help explain why the apparent effect attenuates over time. Those explanations are plausible, but the pooled data do not isolate each one.

“Attenuation” also needs careful wording. A smaller average change at a later time point could reflect slower biological progress, less adherence, different study populations, or a treatment effect that is approaching a plateau. It does not prove that the medicine has stopped working. Nor does it prove that later weight loss necessarily contains a larger share of lean tissue. The correct use of the time point is to specify when the measurement was taken and what the study’s participants and intervention looked like then.

The narrower randomized review shows a similar issue with a different time boundary. Liraglutide studies lasting less than 52 weeks showed an average absolute lean-mass difference of about 0.41 kilograms lower than the comparator. The longer-than-52-week subgroup showed a difference of about 2.65 kilograms lower, but it was based on limited data. Semaglutide showed a larger reported absolute reduction, about 5.44 kilograms, alongside a larger overall weight reduction. These are reasons to examine total weight loss, duration, and sample size together.